Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) have earned a consensus recommendation of “Buy” from the fifteen research firms that are presently covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $52.35.

Several research firms have commented on IART. Zacks Investment Research raised shares of Integra LifeSciences Holdings Corporation from a “sell” rating to a “hold” rating in a research report on Wednesday, August 2nd. Raymond James Financial, Inc. increased their price target on shares of Integra LifeSciences Holdings Corporation from $51.00 to $55.00 and gave the company an “outperform” rating in a research report on Thursday, July 27th. Cantor Fitzgerald set a $65.00 price target on shares of Integra LifeSciences Holdings Corporation and gave the company a “buy” rating in a research report on Wednesday, July 26th. Oppenheimer Holdings, Inc. reissued a “buy” rating on shares of Integra LifeSciences Holdings Corporation in a research report on Wednesday, July 26th. Finally, BidaskClub lowered shares of Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a research report on Monday, July 24th.

Integra LifeSciences Holdings Corporation (NASDAQ IART) traded up 1.41% during mid-day trading on Friday, reaching $49.56. 176,732 shares of the company’s stock were exchanged. Integra LifeSciences Holdings Corporation has a one year low of $40.51 and a one year high of $88.86. The firm has a market capitalization of $3.87 billion, a P/E ratio of 60.44 and a beta of 0.73. The company’s 50-day moving average is $52.73 and its 200 day moving average is $46.89.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last released its quarterly earnings results on Wednesday, July 26th. The life sciences company reported $0.45 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.45. The business had revenue of $282.16 million during the quarter, compared to analyst estimates of $283.58 million. Integra LifeSciences Holdings Corporation had a net margin of 6.27% and a return on equity of 16.79%. The company’s quarterly revenue was up 13.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.40 earnings per share. Equities analysts predict that Integra LifeSciences Holdings Corporation will post $1.90 earnings per share for the current fiscal year.

In related news, Director Barbara B. Hill acquired 5,050 shares of the business’s stock in a transaction dated Tuesday, August 1st. The shares were purchased at an average price of $49.33 per share, for a total transaction of $249,116.50. Following the completion of the acquisition, the director now directly owns 44,772 shares in the company, valued at approximately $2,208,602.76. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Stuart Essig sold 135,000 shares of the company’s stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $49.90, for a total transaction of $6,736,500.00. Following the transaction, the director now owns 2,077,475 shares in the company, valued at approximately $103,666,002.50. The disclosure for this sale can be found here. In the last 90 days, insiders have bought 17,550 shares of company stock worth $864,842. Corporate insiders own 21.50% of the company’s stock.

Several institutional investors have recently bought and sold shares of the stock. LS Investment Advisors LLC increased its position in shares of Integra LifeSciences Holdings Corporation by 4.6% in the second quarter. LS Investment Advisors LLC now owns 2,523 shares of the life sciences company’s stock valued at $138,000 after buying an additional 111 shares during the period. Pinebridge Investments L.P. increased its position in shares of Integra LifeSciences Holdings Corporation by 2.2% in the second quarter. Pinebridge Investments L.P. now owns 7,971 shares of the life sciences company’s stock valued at $435,000 after buying an additional 174 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Integra LifeSciences Holdings Corporation by 8.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,752 shares of the life sciences company’s stock valued at $150,000 after buying an additional 218 shares during the period. Louisiana State Employees Retirement System increased its position in shares of Integra LifeSciences Holdings Corporation by 1.2% in the second quarter. Louisiana State Employees Retirement System now owns 24,600 shares of the life sciences company’s stock valued at $1,341,000 after buying an additional 300 shares during the period. Finally, Pacer Advisors Inc. increased its position in shares of Integra LifeSciences Holdings Corporation by 6.4% in the second quarter. Pacer Advisors Inc. now owns 6,236 shares of the life sciences company’s stock valued at $340,000 after buying an additional 376 shares during the period. Hedge funds and other institutional investors own 86.77% of the company’s stock.

WARNING: “Integra LifeSciences Holdings Corporation (NASDAQ:IART) Receives Consensus Rating of “Buy” from Brokerages” was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.watchlistnews.com/integra-lifesciences-holdings-corporation-nasdaqiart-receives-consensus-rating-of-buy-from-brokerages/1473496.html.

Integra LifeSciences Holdings Corporation Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Analyst Recommendations for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.